表紙
市場調査レポート

脂肪肝疾患:パイプライン分析

Fatty Liver Disease - Pipeline Review, H2 2015

発行 Global Markets Direct 商品コード 232847
出版日 ページ情報 英文 148 Pages
即納可能
価格
本日の銀行送金レート: 1USD=107.50円で換算しております。
Back to Top
脂肪肝疾患:パイプライン分析 Fatty Liver Disease - Pipeline Review, H2 2015
出版日: 2015年09月23日 ページ情報: 英文 148 Pages
概要

脂肪肝疾患とは、肝臓細胞に脂肪が蓄積された状態で、その代表的な原因として、アルコールの過剰摂取が挙げられます。脂肪肝疾患の症状には、腹部の膨満、敏感肌、嘔吐、吐血や下血、記憶の混乱(欠如)、筋肉疲労、黄疸などがあります。

当レポートでは、世界における脂肪肝疾患治療薬のパイプライン製品の概要を提供しており、製品開発、上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などをお届けします。

イントロダクション

  • 調査範囲

脂肪肝疾患の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

脂肪肝疾患:企業で開発中の治療薬

脂肪肝疾患:大学/機関で研究中の治療薬

脂肪肝疾患:パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

脂肪肝疾患:企業で開発中の製品

脂肪肝疾患:大学/機関で研究中の製品

脂肪肝疾患の治療薬開発に従事している企業

  • Arisaph Pharmaceuticals, Inc.
  • ChemoCentryx, Inc.
  • Conatus Pharmaceuticals Inc.
  • Daewoong Pharmaceutical Co., Ltd.
  • Dimerix Bioscience Pty Ltd
  • Dr. Falk Pharma GmbH
  • DURECT Corporation
  • Galmed International Ltd.
  • Generon (Shanghai) Corporation Ltd.
  • Genovate Biotechnology Co., LTD.
  • Gilead Sciences, Inc.
  • Huons Co., Ltd.
  • キョーリン製薬
  • Metabolic Solutions Development Company, LLC
  • Nimbus Therapeutics, LLC
  • Novartis AG
  • Protalix BioTherapeutics, Inc.
  • Raptor Pharmaceuticals Corp.
  • Sancilio & Company, Inc.
  • TCM Biotech International Corp
  • Tobira Therapeutics, Inc.
  • Verva Pharmaceuticals Limited
  • Viking Therapeutics, Inc.
  • Zafgen Inc.
  • Zydus Cadila Healthcare Limited

脂肪肝疾患:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • Aramchol
  • ARI-3037MO
  • C-10
  • CCX-872
  • cenicriviroc mesylate
  • cysteamine DR
  • DMX-300
  • 消化管・代謝性疾患向けABHD6阻害剤
  • DUR-928
  • DWP-10292
  • emricasan
  • etanercept biosimilar
  • F-652
  • HU-002
  • KDT-501
  • MAT-8800
  • MB-12066
  • methazolamide
  • MN-002
  • MSDC-0602
  • MT-2
  • NDI-010976
  • norursodeoxycholic acid
  • oltipraz
  • PCBB-7
  • pradigastat sodium
  • Px-102
  • Px-103
  • Px-104
  • アテローム性動脈硬化症・肝脂肪変性向け遺伝子組み換えタンパク質
  • RT-230
  • saroglitazar
  • SC-410
  • 脂肪肝疾患向け小分子
  • 循環器系・消化管・代謝性疾患向けIKK・TBK1阻害小分子
  • 代謝性・免疫性・消化管疾患向けThem1阻害小分子
  • 脂肪肝疾患向けAMPK活性化小分子
  • 代謝性疾患向けNaCT阻害小分子
  • 循環器系・消化管・代謝性疾患・感染症向け合成ペプチド
  • TCM-606F
  • VK-2809
  • VVP-100-X
  • ZGN-839

脂肪肝疾患:最近のパイプライン動向

脂肪肝疾患:休止中のプロジェクト

脂肪肝疾患:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7088IDB

Summary

Global Markets Direct's, 'Fatty Liver Disease - Pipeline Review, H2 2015', provides an overview of the Fatty Liver Disease's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Fatty Liver Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fatty Liver Disease and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Fatty Liver Disease
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Fatty Liver Disease and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Fatty Liver Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Fatty Liver Disease pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Fatty Liver Disease
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Fatty Liver Disease pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Fatty Liver Disease Overview
  • Therapeutics Development
    • Pipeline Products for Fatty Liver Disease - Overview
    • Pipeline Products for Fatty Liver Disease - Comparative Analysis
  • Fatty Liver Disease - Therapeutics under Development by Companies
  • Fatty Liver Disease - Therapeutics under Investigation by Universities/Institutes
  • Fatty Liver Disease - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Fatty Liver Disease - Products under Development by Companies
  • Fatty Liver Disease - Products under Investigation by Universities/Institutes
  • Fatty Liver Disease - Companies Involved in Therapeutics Development
    • Arisaph Pharmaceuticals, Inc.
    • ChemoCentryx, Inc.
    • Conatus Pharmaceuticals Inc.
    • Daewoong Pharmaceutical Co., Ltd.
    • Dimerix Bioscience Pty Ltd
    • Dr. Falk Pharma GmbH
    • DURECT Corporation
    • Galmed International Ltd.
    • Generon (Shanghai) Corporation Ltd.
    • Genovate Biotechnology Co., LTD.
    • Gilead Sciences, Inc.
    • Huons Co., Ltd.
    • Kyorin Pharmaceutical Co., Ltd.
    • Metabolic Solutions Development Company, LLC
    • Nimbus Therapeutics, LLC
    • Novartis AG
    • Protalix BioTherapeutics, Inc.
    • Raptor Pharmaceuticals Corp.
    • Sancilio & Company, Inc.
    • TCM Biotech International Corp
    • Tobira Therapeutics, Inc.
    • Verva Pharmaceuticals Limited
    • Viking Therapeutics, Inc.
    • Zafgen Inc.
    • Zydus Cadila Healthcare Limited
  • Fatty Liver Disease - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • Aramchol - Drug Profile
    • ARI-3037MO - Drug Profile
    • C-10 - Drug Profile
    • CCX-872 - Drug Profile
    • cenicriviroc mesylate - Drug Profile
    • cysteamine DR - Drug Profile
    • DMX-300 - Drug Profile
    • Drugs to Inhibit ABHD6 for Gastrointestinal and Metabolic Disorders - Drug Profile
    • DUR-928 - Drug Profile
    • DWP-10292 - Drug Profile
    • emricasan - Drug Profile
    • etanercept biosimilar - Drug Profile
    • F-652 - Drug Profile
    • HU-002 - Drug Profile
    • KDT-501 - Drug Profile
    • MAT-8800 - Drug Profile
    • MB-12066 - Drug Profile
    • methazolamide - Drug Profile
    • MN-002 - Drug Profile
    • MSDC-0602 - Drug Profile
    • MT-2 - Drug Profile
    • NDI-010976 - Drug Profile
    • norursodeoxycholic acid - Drug Profile
    • oltipraz - Drug Profile
    • PCBB-7 - Drug Profile
    • pradigastat sodium - Drug Profile
    • Px-102 - Drug Profile
    • Px-103 - Drug Profile
    • Px-104 - Drug Profile
    • Recombinant Protein for Atherosclerosis and Hepatic Steatosis - Drug Profile
    • RT-230 - Drug Profile
    • saroglitazar - Drug Profile
    • SC-410 - Drug Profile
    • Small Molecule for Fatty Liver Disease - Drug Profile
    • Small Molecule to Inhibit IKK and TBK1 for Cardiovascular, Gastrointestinal and Metabolic Disorders - Drug Profile
    • Small Molecule to Inhibit Them1 for Metabolic, Immunology and Gastrointestinal Diseases - Drug Profile
    • Small Molecules to Activate AMPK for Fatty Liver Disease - Drug Profile
    • Small Molecules to Inhibit NaCT for Metabolic Diseases - Drug Profile
    • Synthetic Peptides for Cardiovascular, Gastrointestinal, Metabolic Disorders and Infectious Disease - Drug Profile
    • TCM-606F - Drug Profile
    • VK-2809 - Drug Profile
    • VVP-100-X - Drug Profile
    • ZGN-839 - Drug Profile
  • Fatty Liver Disease - Recent Pipeline Updates
  • Fatty Liver Disease - Dormant Projects
  • Fatty Liver Disease - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Fatty Liver Disease, H2 2015
  • Number of Products under Development for Fatty Liver Disease - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Development by Companies, H2 2015 (Contd..1)
  • Products under Development by Companies, H2 2015 (Contd..2)
  • Products under Investigation by Universities/Institutes, H2 2015
  • Fatty Liver Disease - Pipeline by Arisaph Pharmaceuticals, Inc., H2 2015
  • Fatty Liver Disease - Pipeline by ChemoCentryx, Inc., H2 2015
  • Fatty Liver Disease - Pipeline by Conatus Pharmaceuticals Inc., H2 2015
  • Fatty Liver Disease - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2015
  • Fatty Liver Disease - Pipeline by Dimerix Bioscience Pty Ltd, H2 2015
  • Fatty Liver Disease - Pipeline by Dr. Falk Pharma GmbH, H2 2015
  • Fatty Liver Disease - Pipeline by DURECT Corporation, H2 2015
  • Fatty Liver Disease - Pipeline by Galmed International Ltd., H2 2015
  • Fatty Liver Disease - Pipeline by Generon (Shanghai) Corporation Ltd., H2 2015
  • Fatty Liver Disease - Pipeline by Genovate Biotechnology Co., LTD., H2 2015
  • Fatty Liver Disease - Pipeline by Gilead Sciences, Inc., H2 2015
  • Fatty Liver Disease - Pipeline by Huons Co., Ltd., H2 2015
  • Fatty Liver Disease - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2015
  • Fatty Liver Disease - Pipeline by Metabolic Solutions Development Company, LLC, H2 2015
  • Fatty Liver Disease - Pipeline by Nimbus Therapeutics, LLC, H2 2015
  • Fatty Liver Disease - Pipeline by Novartis AG, H2 2015
  • Fatty Liver Disease - Pipeline by Protalix BioTherapeutics, Inc., H2 2015
  • Fatty Liver Disease - Pipeline by Raptor Pharmaceuticals Corp., H2 2015
  • Fatty Liver Disease - Pipeline by Sancilio & Company, Inc., H2 2015
  • Fatty Liver Disease - Pipeline by TCM Biotech International Corp, H2 2015
  • Fatty Liver Disease - Pipeline by Tobira Therapeutics, Inc., H2 2015
  • Fatty Liver Disease - Pipeline by Verva Pharmaceuticals Limited, H2 2015
  • Fatty Liver Disease - Pipeline by Viking Therapeutics, Inc., H2 2015
  • Fatty Liver Disease - Pipeline by Zafgen Inc., H2 2015
  • Fatty Liver Disease - Pipeline by Zydus Cadila Healthcare Limited, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Fatty Liver Disease Therapeutics - Recent Pipeline Updates, H2 2015
  • Fatty Liver Disease - Dormant Projects, H2 2015
  • Fatty Liver Disease - Dormant Projects (Contd..1), H2 2015

List of Figures

  • Number of Products under Development for Fatty Liver Disease, H2 2015
  • Number of Products under Development for Fatty Liver Disease - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top